The United Kingdom and the United States have secured a landmark bilateral deal that will guarantee zero import taxes on British medicine exports going into the American market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has pledged to increase funding on medicines through the NHS. This move ensures that duties on these vital products will stay at nothing for a timeframe of three years.
This development is in response to previous threats to dramatically increase import taxes on branded drug products, with increases discussed as high as double the cost.
"This agreement between the United Kingdom bolsters the global environment for innovative medicines and brings long-overdue equity to American-British medicine commerce," a statement said.
Commercial Significance
Drugs represent one of the Britain's biggest goods shipped to the America, which is easily the biggest buyer for leading British pharmaceutical firms.
Statistics reveal that in the year to the end of the third quarter, the UK shipped drugs totaling over eleven billion pounds to the US. This figure accounted for nearly one-fifth of all goods exports in that period.
"This deal protects employment, increases investment and paves the way for the UK to become a international leader for life sciences," a government official commented.
Specific UK Commitments
The agreement includes several specific commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it deems new treatments to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a aim to increase overall health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The sum manufacturers must pay back to the NHS to stay within budget will be restricted at 15%. In the past, refunds exceeded twenty percent.
Industry Background
This agreement takes place against a ongoing dispute between the pharmaceutical industry and the UK government over spending levels and NHS adoption.
The disagreement were heightened by arguments that American patients were charged a premium for the equivalent treatments than people in the UK and Europe.
Over the last 18 months, several major manufacturing plans in the UK have been delayed or cancelled, while multi-billion-dollar investments have been pledged toward projects in the United States.
The Science Minister acknowledged that the NHS had to invest a greater share on medicines, noting that its spending on drugs had shrunk as a proportion of its resources over the last ten years.
